{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["PLGA nanoparticles", "cerebral ischemia", "scutellarin", "stroke", "traditional Chinese medicine (TCM)"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35441510", "DateCompleted": {"Year": "2022", "Month": "05", "Day": "03"}, "DateRevised": {"Year": "2022", "Month": "07", "Day": "16"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "04", "Day": "20"}], "Language": ["eng"], "ELocationID": ["10.1021/acs.molpharmaceut.1c00942"], "Journal": {"ISSN": "1543-8392", "JournalIssue": {"Volume": "19", "Issue": "5", "PubDate": {"Year": "2022", "Month": "May", "Day": "02"}}, "Title": "Molecular pharmaceutics", "ISOAbbreviation": "Mol Pharm"}, "ArticleTitle": "Intravenous Administration of Scutellarin Nanoparticles Augments the Protective Effect against Cerebral Ischemia-Reperfusion Injury in Rats.", "Pagination": {"StartPage": "1410", "EndPage": "1421", "MedlinePgn": "1410-1421"}, "Abstract": {"AbstractText": ["This study investigates the protective effect of poly(lactic-<i>co</i>-glycolic acid) (PLGA) nanoparticles (NPs) loaded with scutellarin (SCU), a flavone isolated from the traditional Chinese medicine<i>Erigeron breviscapus</i> (Vant.) Hand.-Mazz., in reducing cerebral ischemia/reperfusion (I/R) injury <i>in vivo</i>. The focal cerebral I/R injury model was established by occluding the middle cerebral artery for 1 h in male Sprague-Dawley (SD) rats. Our SCU-PLGA NPs exhibited an extended <i>in vitro</i> release profile and prolonged blood circulation in rats with cerebral ischemia. More importantly, when administered intravenously once a day for 3 days, SCU-PLGA NPs increased the SCU level in the ischemic brain, compared to free SCU, resulting in a significant reduction of the cerebral infarct volume after cerebral I/R. Furthermore, SCU-PLGA NPs reversed the histopathological changes caused by cerebral I/R injury, as well as attenuated cell apoptosis in the brain tissue, as confirmed by hematoxylin and eosin, and TUNEL staining. Our findings have revealed that our injectable SCU-PLGA NPs provide promising protective effects against cerebral I/R injury, which could be used in combination with the existing conventional thrombolytic therapies to improve stroke management."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants/ Guizhou Provincial Key Laboratory of Pharmaceutics, Guizhou Medical University, Guiyang, Guizhou 550004, China."}, {"Identifier": [], "Affiliation": "Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang, Guizhou 550004, China."}, {"Identifier": [], "Affiliation": "School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, United Kingdom."}], "LastName": "Yang", "ForeName": "Chang", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants/ Guizhou Provincial Key Laboratory of Pharmaceutics, Guizhou Medical University, Guiyang, Guizhou 550004, China."}, {"Identifier": [], "Affiliation": "Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang, Guizhou 550004, China."}], "LastName": "Zhao", "ForeName": "Qing", "Initials": "Q"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants/ Guizhou Provincial Key Laboratory of Pharmaceutics, Guizhou Medical University, Guiyang, Guizhou 550004, China."}, {"Identifier": [], "Affiliation": "Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang, Guizhou 550004, China."}], "LastName": "Yang", "ForeName": "Shanshan", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants/ Guizhou Provincial Key Laboratory of Pharmaceutics, Guizhou Medical University, Guiyang, Guizhou 550004, China."}, {"Identifier": [], "Affiliation": "Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang, Guizhou 550004, China."}], "LastName": "Wang", "ForeName": "Libin", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants/ Guizhou Provincial Key Laboratory of Pharmaceutics, Guizhou Medical University, Guiyang, Guizhou 550004, China."}, {"Identifier": [], "Affiliation": "Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang, Guizhou 550004, China."}], "LastName": "Xu", "ForeName": "Xingyuan", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants/ Guizhou Provincial Key Laboratory of Pharmaceutics, Guizhou Medical University, Guiyang, Guizhou 550004, China."}, {"Identifier": [], "Affiliation": "Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang, Guizhou 550004, China."}], "LastName": "Li", "ForeName": "Lisu", "Initials": "L"}, {"Identifier": ["0000-0001-8671-6533"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, United Kingdom."}], "LastName": "Al-Jamal", "ForeName": "Wafa T", "Initials": "WT"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Mol Pharm", "NlmUniqueID": "101197791", "ISSNLinking": "1543-8384"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Glucuronates"}, {"RegistryNumber": "16IGP0ML9A", "NameOfSubstance": "scutellarin"}, {"RegistryNumber": "7V515PI7F6", "NameOfSubstance": "Apigenin"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Administration, Intravenous"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Apigenin"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Brain Ischemia"}, {"QualifierName": [], "DescriptorName": "Glucuronates"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Nanoparticles"}, {"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": [], "DescriptorName": "Rats, Sprague-Dawley"}, {"QualifierName": ["drug therapy", "prevention & control"], "DescriptorName": "Reperfusion Injury"}], "CoiStatement": "The authors declare\nno\ncompeting financial interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Katan M.; Luft A. Global Burden of Stroke. Semin. Neurol. 2018, 38, 208\u2013211. 10.1055/s-0038-1649503.", "ArticleIdList": ["10.1055/s-0038-1649503", "29791947"]}, {"Citation": "Gao J.; Chen G.; He H.; Liu C.; Xiong X.; Li J.; Wang J. Therapeutic Effects of Breviscapine in Cardiovascular Diseases: A Review. Front. Pharmacol. 2017, 8, 289.10.3389/fphar.2017.00289.", "ArticleIdList": ["10.3389/fphar.2017.00289", "PMC5441392", "28588491"]}, {"Citation": "Chledzik S.; Strawa J.; Matuszek K.; Nazaruk J. Pharmacological Effects of Scutellarin, An Active Component of Genus Scutellaria and Erigeron: A Systematic Review. Am. J. Chin. Med. 2018, 46, 319\u2013337. 10.1142/S0192415X18500167.", "ArticleIdList": ["10.1142/S0192415X18500167", "29433387"]}, {"Citation": "Wang L.; Ma Q. Clinical Benefits and Pharmacology of Scutellarin: A Comprehensive Review. Pharmacol. Ther. 2018, 190, 105\u2013127. 10.1016/j.pharmthera.2018.05.006.", "ArticleIdList": ["10.1016/j.pharmthera.2018.05.006", "29742480"]}, {"Citation": "Xiong F.; Wang H.; Geng K.-k.; Gu N.; Zhu J.-b. Optimized Preparation, Characterization and Biodistribution in Heart of Breviscapine Lipid Emulsion. Chem. Pharm. Bull. 2010, 58, 1455\u20131460. 10.1248/cpb.58.1455.", "ArticleIdList": ["10.1248/cpb.58.1455", "21048336"]}, {"Citation": "Wei L.; Li G.; Yan Y.-D.; Pradhan R.; Kim J. O.; Quan Q. Lipid Emulsion as a Drug Delivery System for Breviscapine: Formulation Development and Optimization. Arch. Pharmacal Res. 2012, 35, 1037\u20131043. 10.1007/s12272-012-0611-z.", "ArticleIdList": ["10.1007/s12272-012-0611-z", "22870813"]}, {"Citation": "Li M.; Zheng Y.; Shan F.-y.; Zhou J.; Gong T.; Zhang Z.-r. Development of Ionic-Complex-Based Nanostructured Lipid Carriers to Improve the Pharmacokinetic Profiles of Breviscapine. Acta Pharmacol. Sin. 2013, 34, 1108\u20131115. 10.1038/aps.2013.43.", "ArticleIdList": ["10.1038/aps.2013.43", "PMC4003023", "23770990"]}, {"Citation": "Liu Z.; Okeke C. I.; Zhang L.; Zhao H.; Li J.; Aggrey M. O.; Li N.; Guo X.; Pang X.; Fan L.; Guo L. Mixed Polyethylene Glycol-Modified Breviscapine-Loaded Solid Lipid Nanoparticles for Improved Brain Bioavailability: Preparation, Characterization, and In Vivo Cerebral Microdialysis Evaluation in Adult Sprague Dawley Rats. AAPS PharmSciTech 2014, 15, 483\u2013496. 10.1208/s12249-014-0080-4.", "ArticleIdList": ["10.1208/s12249-014-0080-4", "PMC3969492", "24482026"]}, {"Citation": "Yang G.; Li Z.; Wu F.; Chen M.; Wang R.; Zhu H.; Li Q.; Yuan Y. Improving Solubility and Bioavailability of Breviscapine with Mesoporous Silica Nanoparticles Prepared Using Ultrasound-Assisted Solution-Enhanced Dispersion by Supercritical Fluids Method. Int. J. Nanomed. 2020, 15, 1661\u20131675. 10.2147/ijn.s238337.", "ArticleIdList": ["10.2147/ijn.s238337", "PMC7071864", "32210559"]}, {"Citation": "Chen Y.; Liu Y.; Xie J.; Zheng Q.; Yue P.; Chen L.; Hu P.; Yang M. Nose to Brain Delivery by Nanosuspensions-Based in situ Gel for Breviscapine. Int. J. Nanomed. 2020, 15, 10435\u201310451. 10.2147/ijn.s265659.", "ArticleIdList": ["10.2147/ijn.s265659", "PMC7767747", "33380794"]}, {"Citation": "Wang H.; Zhang G.; Ma X.; Liu Y.; Feng J.; Park K.; Wang W. Enhanced Encapsulation and Bioavailability of Breviscapine in PLGA Microparticles by Nanocrystal and Water-Soluble Polymer Template Techniques. Eur. J. Pharm. Biopharm. 2017, 115, 177\u2013185. 10.1016/j.ejpb.2017.02.021.", "ArticleIdList": ["10.1016/j.ejpb.2017.02.021", "28263795"]}, {"Citation": "Lin L.-L.; Liu A.-J.; Liu J.-G.; Yu X.-H.; Qin L.-P.; Su D.-F. Protective Effects of Scutellarin and Breviscapine on Brain and Heart Ischemia in Rats. J. Cardiovasc. Pharmacol. 2007, 50, 327\u2013332. 10.1097/fjc.0b013e3180cbd0e7.", "ArticleIdList": ["10.1097/fjc.0b013e3180cbd0e7", "17878763"]}, {"Citation": "Lu J.; Cheng C.; Zhao X.; Liu Q.; Yang P.; Wang Y.; Luo G. PEG-Scutellarin Prodrugs: Synthesis, Water Solubility and Protective Effect on Cerebral Ischemia/Reperfusion Injury. Eur. J. Med. Chem. 2010, 45, 1731\u20131738. 10.1016/j.ejmech.2010.01.006.", "ArticleIdList": ["10.1016/j.ejmech.2010.01.006", "20117861"]}, {"Citation": "Wei Y.; Li L.; Xi Y.; Qian S.; Gao Y.; Zhang J. Sustained Release and Enhanced Bioavailability of Injectable Scutellain-Loaded Bovine Serum Albumin Nanoparticles. Int. J. Pharm. 2014, 476, 142\u2013148. 10.1016/j.ijpharm.2014.09.038.", "ArticleIdList": ["10.1016/j.ijpharm.2014.09.038", "25269007"]}, {"Citation": "Ge Q. H.; Zhou Z.; Zhi X. J.; Ma L. L.; Chen X. H. Pharmacokinetics and Absolute Bioavailability of Breviscapine in Beagle Dogs. Chin. J. Pharmacol. 2003, 34, 618\u2013620."}, {"Citation": "Huang J. M.; Weng W. Y.; Huang X. B.; Ji Y. H.; Chen E. Pharmacokinetics of Scutellarin and Its Aglycone Conjugated Metabolites in Rats. Eur. J. Drug Metab. Pharmacokinet. 2005, 30, 165\u2013170. 10.1007/bf03190615.", "ArticleIdList": ["10.1007/bf03190615", "16250252"]}, {"Citation": "Gao C.; Chen X.; Zhong D. Absorption and Disposition of Scutellarin in Rats: A Pharmacokinetic Explanation for the High Exposure of Its Isomeric Metabolite. Drug Metab. Dispos. 2011, 39, 2034\u20132044. 10.1124/dmd.111.040550.", "ArticleIdList": ["10.1124/dmd.111.040550", "21810967"]}, {"Citation": "Gao C.; Zhang H.; Guo Z.; You T.; Chen X.; Zhong D. Mechanistic Studies on the Absorption and Disposition of Scutellarin in Humans: Selective OATP2B1-Mediated Hepatic Uptake Is a Likely Key Determinant for Its Unique Pharmacokinetic Characteristics. Drug Metab. Dispos. 2012, 40, 2009\u20132020. 10.1124/dmd.112.047183.", "ArticleIdList": ["10.1124/dmd.112.047183", "22822035"]}, {"Citation": "Wang J.; Tan J.; Luo J.; Huang P.; Zhou W.; Chen L.; Long L.; Zhang L.-m.; Zhu B.; Yang L.; Deng D. Y. B. Enhancement of Scutellarin Oral Delivery Efficacy by Vitamin B12-Modified Amphiphilic Chitosan Derivatives to Treat Type II Diabetes Induced-Retinopathy. J. Nanobiotechnol. 2017, 15, 18.10.1186/s12951-017-0251-z.", "ArticleIdList": ["10.1186/s12951-017-0251-z", "PMC5333415", "28249594"]}, {"Citation": "Liu S.; Ho P. C. Formulation Optimization of Scutellarin-Loaded HP-\u03b2-CD/Chitosan Nanoparticles Using Response Surface Methodology with Box\u2013Behnken Design. Asian J. Pharm. Sci. 2017, 12, 378\u2013385. 10.1016/j.ajps.2017.04.003.", "ArticleIdList": ["10.1016/j.ajps.2017.04.003", "PMC7032107", "32104349"]}, {"Citation": "Liu S.; Ho P. C. Intranasal Administration of Brain-Targeted HP-b-CD/Chitosan Nanoparticles for Delivery of Scutellarin, A Compound with Protective Effect in Cerebral Ischaemia. J. Pharm. Pharmacol. 2017, 69, 1495\u20131501. 10.1111/jphp.12797.", "ArticleIdList": ["10.1111/jphp.12797", "28809432"]}, {"Citation": "Ma X.; Yang B.; Zhao Y.; Xie H.; Gong X. Host-Guest Inclusion System of Scutellarin with Polyamine-\u03b2-Cyclodextrin: Preparation, Characterization, and Anti-cancer Activity. Aust. J. Chem. 2015, 68, 946\u2013955. 10.1071/ch14495.", "ArticleIdList": ["10.1071/ch14495"]}, {"Citation": "Liao R.; Liu Y.; Lv P.; Wu D.; Xu M.; Zheng X. Cyclodextrin Pendant Polymer as an Efficient Drug Carrier for Scutellarin. Drug Delivery 2020, 27, 1741\u20131749. 10.1080/10717544.2020.1856223.", "ArticleIdList": ["10.1080/10717544.2020.1856223", "PMC7738300", "33307844"]}, {"Citation": "Xu Y.; Kim C.-S.; Saylor D. M.; Koo D. Polymer Degradation and Drug Delivery in PLGA-based Drug-polymer Applications: A Review of Experiments and Theories. J. Biomed. Mater. Res., Part B 2017, 105, 1692\u20131716. 10.1002/jbm.b.33648.", "ArticleIdList": ["10.1002/jbm.b.33648", "27098357"]}, {"Citation": "Mir M.; Ahmed N.; Rehman A. u. Recent Applications of PLGA based Nanostructures in Drug Delivery. Colloids Surf., B 2017, 159, 217\u2013231. 10.1016/j.colsurfb.2017.07.038.", "ArticleIdList": ["10.1016/j.colsurfb.2017.07.038", "28797972"]}, {"Citation": "Zhong H.; Chan G.; Hu Y.; Hu H.; Ouyang D. A Comprehensive Map of FDA-Approved Pharmaceutical Products. Pharmaceutics 2018, 10, 263.10.3390/pharmaceutics10040263.", "ArticleIdList": ["10.3390/pharmaceutics10040263", "PMC6321070", "30563197"]}, {"Citation": "Huang W.; Zhang C. Tuning the Size of Poly(lactic-co-glycolic acid) (PLGA) Nanoparticles Facricated by Nanoprecipitation. Biotechnol. J. 2018, 13, 1700203.10.1002/biot.201700203.", "ArticleIdList": ["10.1002/biot.201700203", "PMC5924600", "28941234"]}, {"Citation": "Mehrotra A.; Pandit J. K. Preparation and Characterization and Biodistribution Studies of Lomustine Loaded PLGA Nanoparticles by Interfacial Deposition Method. J. Nanomed. Nanotechnol. 2015, 6, 1000328.10.4172/2157-7439.1000328.", "ArticleIdList": ["10.4172/2157-7439.1000328"]}, {"Citation": "Longa E. Z.; Weinstein P. R.; Carlson S.; Cummins R. Reversible Middle Cerebral Artery Occlusion without Craniectomy in Rats. Stroke 1989, 20, 84\u201391. 10.1161/01.str.20.1.84.", "ArticleIdList": ["10.1161/01.str.20.1.84", "2643202"]}, {"Citation": "Ansari S.; Azari H.; McConnell D. J.; Afzal A.; Mocco J. Intraluminal Middle Cerebral Artery Occlusion (MCAO) Model for Ischemic Stroke with Laser Doppler Flowmetry Guidance in Mice. J. Visualized Exp. 2011, 51, e287910.3791/2879.", "ArticleIdList": ["10.3791/2879", "PMC3197429", "21587164"]}, {"Citation": "Li Y.; Lu Y.; Hu J.; Gong Z.; Yang W.; Wang A.; Zheng J.; Liu T.; Chen T.; Hu J.; Mi L.; Li Y.; Lan Y.; Wang Y. Pharmacokinetic Comparison of Scutellarin and Paeoniflorin in Sham-Operated and Middle Cerebral Artery Occlusion Ischemia and Reperfusion Injury Rats after Intravenous Administration of Xin-Shao Formula. Molecules 2016, 21, 1191.10.3390/molecules21091191.", "ArticleIdList": ["10.3390/molecules21091191", "PMC6273475", "27617986"]}, {"Citation": "Yang W.-T.; Wang Y.; Shi Y.-H.; Fu H.; Xu Z.; Xu Q.-Q.; Zheng G.-Q. Herbal Compatibility of Ginseng and Rhubarb Exerts Synergistic Neuroprotection in Cerebral Ischemia/Reperfusion Injury of Rats. Front. Physiol. 2019, 10, 1174.10.3389/fphys.2019.01174.", "ArticleIdList": ["10.3389/fphys.2019.01174", "PMC6753204", "31572219"]}, {"Citation": "Xing J.; Chen X.; Zhong D. Stability of Baicalin in Biological Fluids in vitro. J. Pharm. Biomed. Anal. 2005, 39, 593\u2013600. 10.1016/j.jpba.2005.03.034.", "ArticleIdList": ["10.1016/j.jpba.2005.03.034", "15894449"]}, {"Citation": "Makadia H. K.; Siegel S. J. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers 2011, 3, 1377\u20131397. 10.3390/polym3031377.", "ArticleIdList": ["10.3390/polym3031377", "PMC3347861", "22577513"]}, {"Citation": "Saraiva C.; Pra\u00e7a C.; Ferreira R.; Santos T.; Ferreira L.; Bernardino L. Nanoparticle-Mediated Brain Drug Delivery: Overcoming Blood\u2013Brain Barrier to Treat Neurodegenerative Diseases. J. Controlled Release 2016, 235, 34\u201347. 10.1016/j.jconrel.2016.05.044.", "ArticleIdList": ["10.1016/j.jconrel.2016.05.044", "27208862"]}, {"Citation": "Hu X.-m.; Zhou M.-m.; Hu X.-m.; Zeng F.-d. Neuroprotective Effects of Scutellarin on Rat Neuronal Damage Induced by Cerebral Ischemia/Reperfusion. Acta Pharmacol. Sin. 2005, 26, 1454\u20131459. 10.1111/j.1745-7254.2005.00239.x.", "ArticleIdList": ["10.1111/j.1745-7254.2005.00239.x", "16297343"]}, {"Citation": "Zhang H.-F.; Hu X.-M.; Wang L.-X.; Xu S.-Q.; Zeng F.-D. Protective Effects of Scutellarin Against Cerebral Ischemia in Rats: Evidence for Inhibition of the Apoptosis-Inducing Factor Pathway. Planta Med. 2009, 75, 121\u2013126. 10.1055/s-0028-1088368.", "ArticleIdList": ["10.1055/s-0028-1088368", "19031363"]}, {"Citation": "Maleki S. N.; Aboutaleb N.; Souri F. Berberine Confers Neuroprotection in Coping with Focal Cerebral Ischemia by Targeting Inflammatory Cytokines. J. Chem. Neuroanat. 2018, 87, 54\u201359. 10.1016/j.jchemneu.2017.04.008.", "ArticleIdList": ["10.1016/j.jchemneu.2017.04.008", "PMC5812778", "28495517"]}, {"Citation": "Du H.; He Y.; Pan Y.; Zhao M.; Li Z.; Wang Y.; Yang J.; Wan H. Danhong Injection Attenuates Cerebral Ischemia-Reperfusion Injury in Rats through the Suppression of the Neuroinflammation. Front. Pharmacol. 2021, 12, 561237.10.3389/fphar.2021.561237.", "ArticleIdList": ["10.3389/fphar.2021.561237", "PMC8076794", "33927611"]}, {"Citation": "Fu Y.; Xing R.; Wang L.; Yang L.; Jiang B. Neurovascular Protection of Salvianolic Acid B and Ginsenoside Rg1 Combination Against Acute Ischemic Stroke in Rats. Neuroreport 2021, 32, 1140\u20131146. 10.1097/wnr.0000000000001706.", "ArticleIdList": ["10.1097/wnr.0000000000001706", "34284451"]}, {"Citation": "Majno G.; Joris I. Apoptosis, Oncosis, and Necrosis: An Overview of Cell Death. Am. J. Pathol. 1995, 146, 3\u201315.", "ArticleIdList": ["PMC1870771", "7856735"]}, {"Citation": "Chu X.; Fu X.; Zou L.; Qi C.; Li Z.; Rao Y.; Ma K. Oncosis, the Possible Cell Death Pathway in Astrocytes after Focal Cerebral Ischemia. Brain Res. 2007, 1149, 157\u2013164. 10.1016/j.brainres.2007.02.061.", "ArticleIdList": ["10.1016/j.brainres.2007.02.061", "17433269"]}, {"Citation": "Fricker M.; Tolkovsky A. M.; Borutaite V.; Coleman M.; Brown G. C. Neuronal Cell Death. Physiol. Rev. 2018, 98, 813\u2013880. 10.1152/physrev.00011.2017.", "ArticleIdList": ["10.1152/physrev.00011.2017", "PMC5966715", "29488822"]}, {"Citation": "Bennion D. M.; Steckelings U. M.; Sumners C. Neuroprotection via AT2 Receptor Agonists in Ischemic Stroke. Clin. Sci. 2018, 132, 1055\u20131067. 10.1042/cs20171549.", "ArticleIdList": ["10.1042/cs20171549", "29802210"]}, {"Citation": "Murray V.; Norrving B.; Sandercock P. A. G.; Ter\u00e9nt A.; Wardlaw J. M.; Wester P. The Molecular Basis of Thrombolysis and Its Clinical Application in Stroke. J. Intern. Med. 2010, 267, 191\u2013208. 10.1111/j.1365-2796.2009.02205.x.", "ArticleIdList": ["10.1111/j.1365-2796.2009.02205.x", "20175866"]}, {"Citation": "Hu X.-m.; Zhou M.-m.; Hu X.-m.; Zeng F.-d. Neuroprotective Effects of Scutellarin on Rat Neuronal Damage Induced by Cerebral Ischemia/Reperfusion. Acta Pharmacol. Sin. 2005, 26, 1454\u20131459. 10.1111/j.1745-7254.2005.00239.x.", "ArticleIdList": ["10.1111/j.1745-7254.2005.00239.x", "16297343"]}, {"Citation": "Wang Z.; Yu J.; Wu J.; Qi F.; Wang H.; Wang Z.; Xu Z. Scutellarin Protects Cardiomyocyte Ischemia\u2013Reperfusion Injury by Reducing Apoptosis and Oxidative Stress. Life Sci. 2016, 157, 200\u2013207. 10.1016/j.lfs.2016.01.018.", "ArticleIdList": ["10.1016/j.lfs.2016.01.018", "26775564"]}, {"Citation": "Tang H.; Tang Y.; Li N.; Shi Q.; Guo J.; Shang E.; Duan J.-a. Neuroprotective Effects of Scutellarin and Scutellarein on Repeatedly Cerebral Ischemia-Reperfusion in Rats. Pharmacol., Biochem. Behav. 2014, 118, 51\u201359. 10.1016/j.pbb.2014.01.003.", "ArticleIdList": ["10.1016/j.pbb.2014.01.003", "24423938"]}, {"Citation": "Kadam R. S.; Bourne D. W. A.; Kompella U. B. Nano-Advantage in Enhanced Drug Delivery with Biodegradable Nanoparticles: Contribution of Reduced Clearance. Drug Metab. Dispos. 2012, 40, 1380\u20131388. 10.1124/dmd.112.044925.", "ArticleIdList": ["10.1124/dmd.112.044925", "PMC3382836", "22498894"]}, {"Citation": "Chiu S. S.; Lui E.; Majeed M.; Vishwanatha J. K.; Ranjan A. P.; Maitra A.; Pramanik D.; Smith J. A.; Helson L. Differential Distribution of Intravenous Curcumin Formulations in the Rat Brain. Anticancer Res. 2011, 31, 907\u2013911.", "ArticleIdList": ["PMC3568517", "21498712"]}, {"Citation": "Al-Ahmady Z. S.; Jasim D.; Ahmad S. S.; Wong R.; Haley M.; Coutts G.; Schiessl I.; Allan S. M.; Kostarelos K. Selective Liposomal Transport through Blood Brain Barrier Disruption in Ischemic Stroke Reveals Two Distinct Therapeutic Opportunities. ACS Nano 2019, 13, 12470\u201312486. 10.1021/acsnano.9b01808.", "ArticleIdList": ["10.1021/acsnano.9b01808", "31693858"]}, {"Citation": "Knowland D.; Arac A.; Sekiguchi K. J.; Hsu M.; Lutz S. E.; Perrino J.; Steinberg G. K.; Barres B. A.; Nimmerjahn A.; Agalliu D. Stepwise Recruitment of Transcellular and Paracellular Pathways Underlies Blood-Brain Barrier Breakdown in Stroke. Neuron 2014, 82, 603\u2013617. 10.1016/j.neuron.2014.03.003.", "ArticleIdList": ["10.1016/j.neuron.2014.03.003", "PMC4016169", "24746419"]}, {"Citation": "Saraiva C.; Pra\u00e7a C.; Ferreira R.; Santos T.; Ferreira L.; Bernardino L. Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. J. Controlled Release 2016, 235, 34\u201347. 10.1016/j.jconrel.2016.05.044.", "ArticleIdList": ["10.1016/j.jconrel.2016.05.044", "27208862"]}, {"Citation": "Zhou Y.; Peng Z.; Seven E. S.; Leblanc R. M. Crossing the Blood-Brain Barrier with Nanoparticles. J. Controlled Release 2018, 270, 290\u2013303. 10.1016/j.jconrel.2017.12.015.", "ArticleIdList": ["10.1016/j.jconrel.2017.12.015", "29269142"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "4", "Day": "21", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "5", "Day": "4", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "4", "Day": "20", "Hour": "8", "Minute": "41"}, {"Year": "2022", "Month": "5", "Day": "4"}], "PublicationStatus": "ppublish", "ArticleIdList": ["35441510", "PMC9066406", "10.1021/acs.molpharmaceut.1c00942"]}}], "PubmedBookArticle": []}